Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04949087

Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis(GHOA)

The purpose of this study is to compare the efficacy of intra-articular corticosteroid injections versus platelet-rich plasma injections for non-operative treatment of primary glenohumeral osteoarthritis. The efficacy of intra-articular injections, outside of hyaluronic acid, for the treatment of glenohumeral OA is not known, yet these treatments are commonly used with hopes of providing patients with symptomatic relief that can hopefully delay or prevent the need for shoulder arthroplasty. This study will help elucidate the therapeutic benefit of corticosteroid and Platelet Rich Plasma (PRP) injections in this patient population.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Arthritis Shoulder

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rush University Medical Center

Chicago, Illinois, 60612, United States

Location status: Recruiting

Location contact

Adam Yanke, MD, PhD

PRINCIPAL_INVESTIGATOR

Carla M Edwards, PhD

CONTACT

[email protected]

312-563-5735

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient ≥18y.o. of age
  • Primary glenohumeral arthritis (bone on bone or near bone on bone) that has been previously diagnosed on radiographs and clinical evaluation.
  • Baseline pain level of VAS >4

Exclusion criteria

  • Secondary causes of arthritis (i.e. septic arthritis, rheumatoid arthritis, rotator cuff arthropathy, post-traumatic arthritis)
  • Ipsilateral shoulder surgery within 1 year
  • Any glenohumeral joint injection within 3 months
  • Allergy to lidocaine
  • Known pregnancy
  • Workers compensation case regarding shoulder

Treatment and study plan

Glenohumeral Injection

Procedure

Patients who enroll will be randomized into an injection group, and then will undergo the specified injection at one time point only.

Primary outcomes

  1. Visual Analog Scale-Pain (VAS)

    Time frame: 12 weeks

    Validated patient-reported metric scale of pain: no pain (0-4 mm), mild pain(5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm)

Study contacts

Contact information is provided by the study sponsor or research team.

Carla M Edwards, PhD

CONTACT

[email protected]

312.563.5735

Sponsors and collaborators

Lead sponsor

Rush University Medical Center

Other

Registry information

Official study title

Prospective, Double Blind, Randomized Control Trial Comparing the Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis

Acronym: GHOA

Important dates

Study start
2023
Primary completion
2027
Study completion
2028
First posted
Jul 2, 2021
Registry last updated
Feb 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.